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Table 1. Associations between decreasing mean levels of cal-
cineurin inhibitors and outcomes in patients who had non-
myeloablative hematopoietic cell transplantation. Mean levels
of cyclosporine and tacrolimus within the first month after
transplant were 340 ng/mL and 12 ng/mL, respectively. Hazard
ratios (HR) are shown according to 10% decrements relative to
mean levels of respective calcineurin inhibitor.
Datum
Cyclosporine (n5280) Tacrolimus (n5127)
HR (95% CI) P HR (95% CI) P
Acute GVHD 2-4 1.18 (1.10-1.26) <0.0001 1.04 (0.93-1.15) 0.51
Acute GVHD 3-4 1.13 (0.99-1.28) 0.06 1.22 (0.94-1.58) 0.13
Chronic GVHD 0.99 (0.90-1.08) 0.81 0.90 (0.83-1.00) 0.04
Relapse 1.07 (0.93-1.22) 0.35 0.97 (0.88-1.08) 0.62
NRM 1.31 (1.12-1.54) 0.0009 1.21 (0.91-1.62) 0.19
OM 1.10 (1.01-1.19) 0.02 1.07 (0.97-1.18) 0.19
GVHD – graft versus host disease, NRM – non relapse mortality, OM –
overall mortality.
S168 Oral Presentations2007). The impact of statins on alloreactivity was reproducible when
human cells where studied in vitro and recent retrospective clinical
studies demonstrated that statin treatmentwas associatedwith reduced
acute GvHD and chronic GvHD in patients with cyclosporine-based
immunosuppression. Downstreammetabolites of the pathway are far-
nesylpyrophosphates, geranylgeranylpyrophosphates and squalene.
Currently, the relevance of the different metabolites for the immuno-
modulatory effect of statins on GvHD and immune reconstitution is
unclear. Therefore, we applied Farnesyl-transferase inhibitor (FTI)
and Geranylgeranyl-transferase inhibitor (GGTI) or Zaragocic acid
tomurineBMTrecipients.Treatment ofwithFTIandGGTI reduced
GvHD severity and prolonged survival significantly (vehicle versus
FTI p 5 0.0001, vehicle versus GGTI p 5 0.0007) in 2 different
BMTmodels. Improved survival was paralleled by lower serum levels
of TNF-a (vehicle vs FTI p\0.01) and MCP-1 (vehicle vs FTI p\
0.01 or vsGGTI p\0.05). Mechanistically we observed that geranyl-
geranylation and farnesylationwere required for cytoskeletal organiza-
tion and migration of antigen presenting cells (APC) in vitro.
Compatible with this observation, bioluminescence based tracking
demonstrated reduced recruitment of APC towards lymphoid organs
in vivo. FTI and GGTI treatment resulted in reduced ERK1/2 signal-
ing inT cells and affected their alloantigen driven expansion. Interfer-
ing with donor alloreactive T cell expansion in vivo led to increased
thymic cellularity, higher thymocyte counts and a more diverse TCR
repertoire as determined by PCR based spectratyping. These effects
were not seen when squalene production was blocked. FTI and
GGTI did not compromise donor peripheral T cell function since
B-cell lymphoma rejection and MCMV immunity remained intact.In
summary we observed an immunomodulatory effect of FTI/GGTI
onGvHDwhich enhanced numerically intact, diverse immune recon-
stitution with functional anti-tumor and anti-MCMV effects. These
studies are the first to delineate the relative contributions of Farne-
syl-transferase andGeranylgeranyl-transferase to the protective effects
against GvHD observed under statin treatment.44
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To determine whether calcineurin inhibitor (CNI) blood concen-
trations within the first month after allogeneic hematopoietic cell
transplantation (HCT) correlated with the onset of graft-versus-
host disease (GVHD) and other outcomes, we retrospectively ana-
lyzed data from 1181 patients with hematologic malignancies who
had HCT from HLA-matched related (n 5 634) or unrelated (n 5
547) donors at a single institution between 2001 and 2009. Aftermye-
loablative HCT (n 5 774), lower CNI blood levels were not associ-
ated with higher risks for acute or chronic GVHD, even though
higher cumulative doses of glucocorticoids during the first 100 days
were required for treatment of acuteGVHDamongpatients given ta-
crolimus prophylaxis (p5 0.007). In contrast, after nonmyeloablative
HCT (n5 407), lower cyclosporine blood levels were associatedwith
increased risks of grade 2-4 and 3-4 acute GVHD (hazard ratio [HR]
5 1.18, 95% confidence interval [CI]1.10-1.26, p\0.0001; and HR
5 1.13, 95%CI 0.99-1.28, p5 0.06, respectively), non relapse mor-
tality (NRM) (HR5 1.31 95%CI 1.12-1.54, p5 0.0009) and overall
mortality (OM) (HR51.10, 95%CI1.01-1.19, p50.02).In addition,
each 10% increment inmean cumulative blood levels of cyclosporine
above 340 ng/ml, was associated with a 4.3 mg/kg reduction of the
cumulative glucocorticoids dose during the first 100 days after
HCT (p\0.0001). Cyclosporine blood levels within the first month
after HCT were not associated with risks of chronic GVHD and re-
current malignancy after nonmyeloablative HCT. Among patients
given tacrolimus after nonmyeloablative HCT, a potential similar
trend of CNI-associated GVHD-protection was observed. HigherCNI blood levels were not associated with renal toxicity. We con-
clude that higher CSP blood levels during the first month after non-
myeloablative HCT confer protection against acute GVHD that
translates into reduced risks of NRM and OM without affecting
the risks of chronic GVHD or recurrent malignancy.45
HIGH FREQUENCY OF ALLOANTIGEN-SPECIFIC T-Regs IN HUMAN
BLOOD ALLOW RAPID EX VIVO EXPANSION FOR ADOPTIVE THERAPY
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Adoptive transfer of regulatoryT (Treg) cells prevents allograft re-
jection and graft-vs-host disease (GVHD) in experimental animals.
Since Treg function is driven by recognition of specific antigen, we
have established a technique for selective expansion of human allo-
specific Treg ex vivo. In this study, we show that a high frequency
ofCD41CD251CD127-Tregs inhumanblooddo recognize specific
alloantigen and can be expanded to numbers adequate for adoptive
immunotherapy trials. Treg were isolated from normal human blood
and stimulated by HLA-mismatched APC’s, in the presence of IL-2
and IL-15 to amplify the proliferative responses, and sirolimus to sup-
press non-Tregs. The precursor frequency of antigen specific Tregs
was 1.02 % (95% Confidence Interval; 0.65 - 1.59) and non-Tregs
1.56% (95% C.I; 0.94 - 2.55), as calculated by Limiting Dilution
Analysis. Tregs showed a duplication time of approximately 24 hours
in the presence alloantigen, cytokines and sirolimus, and were ex-
panded in vitro by 793 (95%C.I; 480 - 1107) fold in a 12 day period.
Purified Tregs were labeled with CFSE before culture with alloanti-
gen, cytokines and sirolimus. After 12 days in culture, flow-sorted
CFSE-lowTregs exhibited 90% suppression against CD25-negative
CD4 T cell responses up to ratios of 1:20; in contrast, CFSE-high
Tregs were not suppressive. CFSE-low Tregs did not suppress the
proliferation of non-Tregs against third party alloantigen, demon-
strating that their suppressionwas antigen specific. Ex vivo expanded,
antigen specific Tregs maintained high expression of Foxp3, lym-
phoid homing receptorCD62L and chemokine receptorCCR7, pre-
dicting that they will remain functional and able to migrate to
lymphoid tissues in vivo. The expanded Tregs produced IL-10,
TGF-b and expressed cytoplasmic CTLA-4 to significantly higher
accounts compared to non-Tregs, suggesting these molecules may
be involved in the mechanism of regulation. Our data provide a plat-
form for the selective expansion of Tregs against major histocompat-
ibility antigens. This magnitude of expansion predicts the feasibility
of conducting translational clinical trials for prevention of GVHD.
